01—Abstract
Summary
Summary of the 10-K filed February 24, 2022. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific's FY2021 10-K shows a company at a major inflection point.
Revenue grew 22% to $39.21 billiona (organic growth of 17%), GAAP operating income rose 29% to $10.03 billion, and GAAP diluted EPS climbed 22% to $19.46 (adjusted EPS $25.13, up 28%). Strength was broad-based, with COVID-19-related product sales of $9.23 billion, meaningful contributions from vaccine and therapy manufacturing, and recovery in the Analytical Instruments segment. Growth was partly fueled by acquisitions, most notably the $15.99 billion cash purchase of PPD, Inc. completed December 8, 2021, along with Mesa Biotech, PeproTech and a viral vector business.
The balance sheet changed materially. Total debt rose from $21.7 billion to $34.9 billionb, goodwill jumped to $41.9 billion, and total assets reached $95.1 billion, up from $69.1 billion. Cash fell to $4.5 billion from $10.3 billion.
Free cash flow was roughly flat at $6.8 billionc, and management repurchased $2.0 billion of stock in 2021 plus another $2.0 billion in early 2022, leaving $1.0 billion of authorization. Net leverage and the resulting interest burden are now key considerations, and the company has a 3.5x minimum interest coverage covenant on its revolver. Goodwill and intangibles total roughly $62 billion, so future impairment risk is significant if acquired businesses underperform.
Management guides to a 2022 GAAP effective tax rate of 9-11% and adjusted tax rate near 13%, and capex of $2.5d-2.7 billion. Investors should weigh the strong operating momentum and pandemic-driven demand against the risk that COVID-related revenue normalizes, the execution risk of integrating PPD, and the higher leverage taken on to fund the deal. Legal and environmental exposures appear manageable, with product liability accruals of $216 million and environmental liabilities of $65 million.
02—Key points
Key Highlights
- Revenue up 22% to $39.2B; organic growth of 17%, with acquisitions contributing 3 points and currency 2 points.
- GAAP operating margin expanded to 25.6% from 24.2%; adjusted operating margin reached 31.0%.
- GAAP diluted EPS of $19.46 (+22%); adjusted EPS of $25.13 (+28%).
- COVID-19-related product sales of $9.23B in 2021 versus $6.63B in 2020, with management guiding that some benefit continues into 2022 but is uncertain.
- Completed the $15.99B cash acquisition of PPD, funded largely with new debt; total debt rose to $34.9B from $21.7B.
- Returned $2.0B via buybacks in 2021 and $2.0B more in early Q1 2022; $1.0B authorization remaining as of February 24, 2022.
- Goodwill of $41.9B and definite-lived intangibles of $18.9B create meaningful impairment exposure if acquired businesses underperform.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2021filed February 24, 2022Financial Statements
FY2021 against FY2020
| Line item | FY2021FY2020 | Change |
|---|---|---|
| Revenue | $39.21B$32.22B | +21.7% |
| R&D Expenses | $1.41B$1.18B | +19.1% |
| SG&A Expenses | $8.01B$6.93B | +15.5% |
| Operating Expenses | $29.18B$24.42B | +19.5% |
| Operating Income | $10.03B$7.79B | +28.7% |
| Interest Expense | $536.00M$553.00M | −3.1% |
| Net Income | $7.72B$6.38B | +21.2% |
| EPS (Basic) | $19.62$16.09 | +21.9% |
| EPS (Diluted) | $19.46$15.96 | +21.9% |
| Shares Outstanding (Basic) | 394.00M396.00M | −0.5% |
| Shares Outstanding (Diluted) | 397.00M399.00M | −0.5% |
05—Questions
Frequently Asked Questions
What drove Thermo Fisher's strong 2021 revenue growth?
Revenue grew 22% to $39.2B, with 17% organic growth. The main drivers were COVID-19 testing and therapeutics/vaccine-related demand, a recovery in academic, government, and industrial markets, and the contribution of acquisitions, especially PPD (closed December 2021). Pharma and biotech demand was particularly strong.
How much debt did Thermo Fisher take on, and is it a concern?
Total debt rose to $34.9B at year-end 2021 from $21.7B, mainly to fund PPD. The company has a $5.0B revolving facility and says cash flow should cover obligations, but leverage is materially higher, raising interest expense sensitivity and covenant considerations (minimum 3.5x interest coverage). Management has indicated it will prioritize debt reduction alongside buybacks and acquisitions.
Is the company's COVID-19 revenue sustainable?
Management says COVID-related benefits are expected to continue into 2022, but the duration and size depend on customer testing demand and vaccine and therapy demand, which it describes as uncertain. Investors should treat the $9.23B of 2021 COVID-related product sales as a non-recurring-risk component of the top line.
What is the outlook for taxes and capital spending in 2022?
The company expects a 2022 GAAP effective tax rate of 9% to 11% and an adjusted tax rate of about 13%. Capital expenditures are expected to be $2.5 to $2.7 billion, net of disposals. Cash taxes paid were $2.18B in 2021, above book tax expense, largely due to non-deductible intangible amortization.
What are the main risks from the goodwill and intangibles on the balance sheet?
Goodwill ($41.9B) and indefinite-lived intangibles ($1.2B) are tested annually and no impairments were recorded in 2021, but a decline in acquired business performance, peer trading multiples, or higher discount rates could trigger write-downs. Definite-lived intangibles of $18.9B are amortized (about $2.5B expected in 2022), which weighs on GAAP earnings but is excluded from adjusted metrics.
06—Continue